Correlations between Circulating and Tumor-Infiltrating CD4(+) T Cell Subsets with Immune Checkpoints in Colorectal Cancer

T regulatory cells (Tregs) play different roles in the regulation of anti-tumor immunity in colorectal cancer (CRC), depending on the presence of different Treg subsets. We investigated correlations between different CD4(+) Treg/T cell subsets in CRC patients with immune checkpoint-expressing CD4(+) T cells. Positive correlations were observed between levels of different immune checkpoint-expressing CD4(+) T cells, including PD-1, TIM-3, LAG-3, and CTLA-4 with FoxP3(+) Tregs, Helios(+) T cells, FoxP3(+)Helios(+) Tregs, and FoxP3(+)Helios(−) Tregs in the tumor microenvironment (TME). However, negative correlations were observed between levels of these immune checkpoint-expressing CD4(+) T with FoxP3(−)Helios(−) T cells in the TME. These correlations in the TME highlight the role of cancer cells in the upregulation of IC-expressing Tregs. Additionally, positive correlations were observed between levels of FoxP3(+) Tregs, Helios(+) T cells, FoxP3(+)Helios(+) Tregs, and FoxP3(+)Helios(−) Tregs and levels of CD4(+)CTLA-4(+) T cells and CD4(+)PD-1(+) T cells in peripheral blood mononuclear cells (PBMCs) and normal tissue-infiltrating lymphocytes (NILs). These observations suggest that CTLA-4 and PD-1 expressions on CD4(+) T cell subsets are not induced only by the TME. This is the first study to investigate the correlations of different FoxP3(+/−)Helios(+/−) T cell subsets with immune checkpoint-expressing CD4(+) T cells in CRC patients. Our data demonstrated strong correlations between FoxP3(+/)Helios(+/−) Tregs but not FoxP3(−)Helios(+/−) non-Tregs and multiple immune checkpoints, especially in the TME, providing a rationale for targeting these cells with highly immunosuppressive characteristics. Understanding the correlations between different immune checkpoints and Treg/T cell subsets in cancer patients could improve our knowledge of the underlying mechanisms of Treg-mediated immunosuppression in cancer.